Allan E. Siperstein

Allan E. Siperstein

Auto-generated profile, based on publicly available information

Allan E. Siperstein

Department of Endocrine Surgery, Cleveland Clinic, Cleveland, OH

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2000 in Cancer
Verified
Journal Article
Open access
PDF file
EKElectron Kebebew
Electron Kebebew
PIPhilip H. G. Ituarte
Philip H. G. Ituarte
ASAllan E. Siperstein
Allan E. Siperstein
QDQuan-Yang Duh
Quan-Yang Duh
OCOrlo H. Clark
Orlo H. Clark
BACKGROUND The clinical courses of patients with medullary thyroid carcinoma (MTC) vary, and a number of prognostic factors have been studied, but the significance of some of these factors remains controversial. METHODS The study group consisted of 104 patients with MTC or C‐cell hyperplasia managed at the hospitals of the University of California, San Francisco, between January 1960 and December 1998. Patients were classified as having sporadic MTC, familial non‐multiple endocrine neoplasia (MEN) MTC, MEN 2A, or MEN 2B. The TNM, European Organization for Research and Treatment of Cancer (EORTC), National Thyroid Cancer Treatment Cooperative Study (NTCTCS), and Surveillance, Epidemiology, and End Results (SEER) extent‐of‐disease stages were determined for each patient. The predictive values of these staging or prognostic scoring systems were compared by calculating the proportion of variance explained (PVE) for each system. RESULTS Fifty‐six percent of the patients had sporadic MTC, 22% had familial MTC, 15% had MEN 2A, and 7% had MEN 2B. The overall average age at diagnosis was 38 years, and patients with sporadic MTC presented at an older age (P < 0.05). Thirty‐two percent of the patients with hereditary MTC were diagnosed by screening (genetic and/or biochemical). These patients had a lower incidence of cervical lymph node metastasis (P < 0.05) and 94.7% were cured at last follow‐up (P < 0.0001) compared with patients not screened. Patients with sporadic MTC who had systemic symptoms (diarrhea, bone pain, or flushing) had widely metastatic MTC and 33.3% of those patients died within 5 years. Overall, 49.4% of the patients were cured, 12.3% had recurrent MTC, and 38.3% had persistent MTC. The mean follow‐up time was 8.6 years (median, 5.0 years) with 10.7% (n=11) and 13.5% (n=14) cause specific mortality at 5 and 10 years, respectively. Patients with persistent or recurrent MTC who died of MTC lived for an average of 3.6 years (ranging from 1 month to 23.7 years). Patients who had total or subtotal thyroidectomy were less likely to have persistent or recurrent MTC (P < 0.05), and patients who had total thyroidectomy with cervical lymph node clearance required fewer reoperations for persistent or recurrent MTC (P < 0.05) than patients who underwent lesser procedures. In univariate analysis, age, gender, clinical presentation, TNM stage, sporadic/hereditary MTC, distant metastasis, and extent of thyroidectomy were significant prognostic factors. Only age and stage, however, remained independent prognostic factors in multivariate analysis. The TNM, EORTC, NTCTCS, and SEER staging systems were all accurate predictors of survival, but the EORTC prognostic scoring system had the highest PVE in this cohort. CONCLUSIONS Screening for MTC and early treatment (total thyroidectomy with central neck lymph node clearance) had nearly a 100% cure rate. Patients with postoperative hypercalcitoninemia without clinical or radiologic evidence of residual tumor after apparently curative surgery may enjoy long term survival but have occult MTC. Only patient age at presentation and TNM stage were independent predictors of survival. The EORTC criteria, which included the greatest number of significant prognostic factors in our cohort, had the highest predictive value. Cancer 2000;88:1139–48. © 2000 American Cancer Society.

1 January 2010 in Archives of Surgery
Verified
Journal Article
Open access
PDF file
SRStanley J. Rogers
Stanley J. Rogers
JCJohn P. Cello
John P. Cello
JHJan K. Horn
Jan K. Horn
ASAllan E. Siperstein
Allan E. Siperstein
WSWilliam P. Schecter
William P. Schecter
HHHobart W. Harris
Hobart W. Harris
Research from JAMA Surgery — Prospective Randomized Trial of LC+LCBDE vs ERCP/S+LC for Common Bile Duct Stone Disease

13 February 2004 in Cancer
Verified
Journal Article
Open access
PDF file
ADAlessandra D'AVanzo
Alessandra D'AVanzo
PTPatrick Treseler
Patrick Treseler
PIPhilip H. G. Ituarte
Philip H. G. Ituarte
MWMariwil Wong
Mariwil Wong
LSLeanne Streja
Leanne Streja
OCOrlo H. Clark
Orlo H. Clark
BACKGROUND: Follicular thyroid carcinoma (FTC) is the second most common thyroid malignancy after papillary thyroid carcinoma. The authors studied the clinical course of 132 patients with FTC to determine whether there was a direct relation between the histologic degree of invasion, tumor recurrence, and patient survival.METHODS: The 132 patients in the study population underwent 182 thyroid carcinoma–related operations, and their mean follow‐up was 7.5 years (median:,6 years; range, 0–39 years). The following criteria were used to define malignant follicular neoplasms: 1) minimally invasive, tumor invasion through the entire thickness of the tumor capsule; 2) moderately invasive, tumor with angioinvasion (with or without capsular invasion); and 3) widely invasive, broad area or areas of transcapsular invasion of thyroid and extrathyroidal tissue. Forty‐five of 119 patients (37.8%) presented with minimally invasive FTC (capsular invasion only), 50 patients (42%) presented with moderately invasive FTC (angioinvasion with or without capsular invasion), and 24 patients (20%) presented with widely invasive FTC. At presentation, 12 patients (9%) had distant metastases, and 8 patients (6%) had lymph node metastases.RESULTS: Excluding 12 patients who presented with distant metastases, 21 patients (16%) developed recurrent metastases 6 months after their initial treatment. Among 45 patients with capsular invasion only, 6 patients (13%) developed recurrent or persistent disease, and 5 patients (11%) died. Of the 50 patients who had angioinvasion with or without capsular invasion, 10 patients (20%) developed recurrent or persistent disease, and 7 patients (14%) died. Patients who had angioinvasion with or without capsular invasion had a less favorable prognosis compared with patients who had capsular invasion only (P < 0.0001). Among patients who had widely invasive FTC, 9 of 24 patients (38%) developed recurrent disease, and 8 patients (33%) died; in addition, 7 of the other 24 patients (29%) had persistent disease and died. The overall death rate for patients with widely invasive FTC was 62%. Patients with persistent disease had a poorer prognosis compared with patients who had recurrent disease (P < 0.0001). Twenty‐eight patients (21%) in the entire group died of FTC.CONCLUSIONS: In the current retrospective investigation, the authors demonstrate that patients with minimally invasive FTC (capsular invasion only) had a slightly better survival rate at 5 years (98%) compared with patients who had angioinvasion with or without capsular invasion (80%) and had better survival compared with patients who had widely invasive FTC (38%). Other (but not all) reports in the literature support the findings that FTC with angioinvasion is more aggressive than FTC with only capsular invasion yet is less aggressive than widely invasive FTC. The authors conclude that FTC no longer should be classified as either minimally invasive or widely invasive; rather, they recommend classifying FTC as minimally invasive, moderately invasive, or widely invasive, because prognosis varies according to these groupings. Cancer 2004. © 2004 American Cancer Society.

1 February 2005 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
AHAmir H. Hamrahian
Amir H. Hamrahian
AIAdriana G. Ioachimescu
Adriana G. Ioachimescu
ERErick M. Remer
Erick M. Remer
GMGaspar Motta-Ramirez
Gaspar Motta-Ramirez
HBHari Bogabathina
Hari Bogabathina
EBEmmanuel L. Bravo
Emmanuel L. Bravo
Radiological characterization of an adrenal tumor as adenoma may decrease the need for follow-up imaging studies, biopsies, and unnecessary adrenalectomies. We retrospectively reviewed 299 adrenalectomies in 290 patients at Cleveland Clinic Foundation over a recent 5-yr period to assess the value of noncontrast Hounsfield units (HU) in characterizing whether an adrenal mass is adenoma or nonadenoma. The mean (± sd) HU value for the adrenocortical adenoma/hyperplasia group was 16.2 ± 13.6 and significantly lower (P < 0.0001) than primary adrenocortical cancers (36.9 ± 4.1), metastases (39.2 ± 15.2), and pheochromocytomas (38.6 ± 8.2). The sensitivity and specificity for 10- and 20-HU cutoff values to differentiate adenomas/hyperplasias from nonadenomas were 40.5 and 100% and 58.2 and 96.9%, respectively. The size of the adrenal tumor had less value with only 40.7 and 81.3% sensitivity and 94.7 and 61.4% specificity for 2- and 4-cm cutoff values. A combination of less than or equal to 4-cm adrenal mass size and noncontrast computed tomography HU less than or equal to 20 had 42.1% sensitivity and 100% specificity. Our study, the largest with surgical histopathology as the gold standard for diagnosis, supports a noncontrast computed tomography attenuation value of 10 HU as a safe cutoff value to differentiate adrenal adenomas/hyperplasias from nonadenomas.

1 July 2007 in Surgery
Verified
Journal Article
Closed access
PMPeter J. Mazzaglia
Peter J. Mazzaglia
EBEren Berber
Eren Berber
MMMira Milas
Mira Milas
ASAllan E. Siperstein
Allan E. Siperstein

1 August 1996 in Archives of Surgery
Verified
Journal Article
Closed access
PDF file
WSWen Shen
Wen Shen
MDMete Düren
Mete Düren
EMEugene Morita
Eugene Morita
CHCharles Higgins
Charles Higgins
QDQuan-Yang Duh
Quan-Yang Duh
OCOrlo H. Clark
Orlo H. Clark
Research from JAMA Surgery — Reoperation for Persistent or Recurrent Primary Hyperparathyroidism